Vincristine

Vincristine

SCHEMBL3999

CC[C@]1(O)C[C@H]2CN(CCc3c([nH]c4ccccc34)[C@@](C(=O)OC)(c3cc4c(cc3OC)N(C=O)[C@H]3[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]5(CC)C=CCN6CC[C@]43[C@@H]65)C2)C1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8

The experimentally established mechanism targets of Vincristine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TUBB4A known ✓ P04350 6/20 1.00
TUBB known ✓ P07437 6/20 1.00
TUBA3C known ✓ P0DPH7 6/20 1.00
TUBA1B known ✓ P68363 6/20 1.00
TUBA4A known ✓ P68366 6/20 1.00
TUBB4B known ✓ P68371 6/20 1.00
TUBB3 known ✓ Q13509 6/20 1.00
TUBB2A known ✓ Q13885 6/20 1.00
TUBB8 known ✓ Q3ZCM7 6/20 1.00
TUBA3E known ✓ Q6PEY2 6/20 1.00
TUBA1A known ✓ Q71U36 6/20 1.00
TUBA1C known ✓ Q9BQE3 6/20 1.00
TUBB6 known ✓ Q9BUF5 6/20 1.00
TUBB2B known ✓ Q9BVA1 6/20 1.00
TUBB1 known ✓ Q9H4B7 6/20 1.00
LMNA P02545 6/20 1.00
CYP3A4 P08684 6/20 1.00
HIF1A Q16665 5/20 1.00
ALOX15 P16050 5/20 1.00
TP53 P04637 4/20 1.00

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Vincristine SCHEMBL13321219 1.00 LMNA (1.00) LMNACYP3A4TUBB4ATUBBTUBA3C
Vincristine SCHEMBL13662639 1.00 LMNA (1.00) LMNACYP3A4TUBB4ATUBBTUBA3C
Vincristine SCHEMBL14177979 1.00 LMNA (1.00) LMNACYP3A4TUBB4ATUBBTUBA3C
Vincristine SCHEMBL13840950 1.00 LMNA (1.00) LMNACYP3A4TUBB4ATUBBTUBA3C
Vincristine SCHEMBL4769981 1.00 LMNA (1.00) LMNACYP3A4TUBB4ATUBBTUBA3C
Vincristine SCHEMBL13300978 1.00 LMNA (1.00) LMNACYP3A4TUBB4ATUBBTUBA3C
Vincristine SCHEMBL15474330 1.00 LMNA (1.00) LMNACYP3A4TUBB4ATUBBTUBA3C
Vincristine SCHEMBL18402663 1.00 LMNA (1.00) LMNACYP3A4TUBB4ATUBBTUBA3C
Vincristine SCHEMBL15866613 1.00 LMNA (1.00) LMNACYP3A4TUBB4ATUBBTUBA3C
Vincristine SCHEMBL19522762 1.00 LMNA (1.00) LMNACYP3A4TUBB4ATUBBTUBA3C

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Appears in 47703 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3607938-B1 PHARMACEUTICAL COMPOSITION SOVIC BRKICIC LJILJANA (HR) 2026-05-27 EP claimed
EP-3727367-B1 VITAMIN K2 COMPOSITIONS FOR USE IN THE TREATMENT OF DRUG INDUCED NEUROPATHY SYNERGIA LIFE SCIENCES PVT LTD (IN) 2026-05-27 EP claimed
EP-3841097-B1 2,6-BIS(((1H-BENZO[D]IMIDAZOL-2-YL)THIO)METHYL)PYRIDINE AND N2,N6-DIBENZYLPYRIDINE-2,6-DICARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS AS PHOSPHOINOSITIDE 3-KINASE (PI3K) INHIBITORS FOR TREATING CANCER BIOMEDICAL RES FOUNDATION OF THE ACADEMY OF ATHENS BRFAA (GR) 2026-05-20 EP claimed
US-20260130919-A1 PRALATREXATE AND COP COMBINATION FOR THE TREATMENT OF PATIENTS WITH PERIPHERAL T CELL LYMPHOMA Acrotech Biopharma Inc. (US) 2026-05-14 US claimed
US-20260132141-A1 PROTEIN PHOSPHATASE 2A ACTIVATORS UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) 2026-05-14 US claimed
EP-4739317-A1 PRALATREXATE AND COP COMBINATION FOR THE TREATMENT OF PATIENTS WITH PERIPHERAL T CELL LYMPHOMA Acrotech Biopharma Inc. (US) 2026-05-13 EP claimed
US-20260125428-A1 SYNTHETIC TRIPLEX PEPTIDE NUCLEIC ACID-BASED INHIBITORS FOR CANCER THERAPY UNIV CONNECTICUT (US) 2026-05-07 US claimed
EP-3978473-B1 COMPOUND CONTAINING AN INDOLEACETIC ACID CORE STRUCTURE AND USE THEREOF BEIJING AN JIAN XI BIO MEDICAL TECH CO LTD (CN) 2026-05-06 EP claimed
EP-4735116-A2 ANTI-TRAILR2 ANTIGEN-BINDING PROTEINS AND USES THEREOF ODYSSEY THERAPEUTICS, INC. (US) 2026-05-06 EP claimed
EP-3856736-B1 NOVEL COMPOUNDS AS NADPH OXIDASE INHIBITORS CALLIDITAS THERAPEUTICS SUISSE SA (CH) 2026-05-06 EP claimed
US-4935445-A Method for treatment tumors sensitive to treatment with anti-tumor agents employing Norverapamil MERRY STEPHEN (GB) 1990-06-19 US claimed
US-4923876-A VINCRISTINE SULFATE, CITRATE BUFFER CETUS CORPORATION (US) 1990-05-08 US claimed
EP-0335966-A4 VASOCONSTRICTIVE SUBSTANCES IN COMBINATION WITH CYTOTOXIC AGENTS. MATRIX PHARMA INC (US) 1990-02-20 EP claimed
US-4883805-A LEUKEMIA TREATMENT TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) 1989-11-28 US claimed
EP-0335966-A1 VASOCONSTRICTIVE SUBSTANCES IN COMBINATION WITH CYTOTOXIC AGENTS MATRIX PHARMACEUTICALS, INC. (US) 1989-10-11 EP claimed
WO-1989002734-A1 VASOCONSTRICTIVE SUBSTANCES IN COMBINATION WITH CYTOTOXIC AGENTS MATRIX PHARMACEUTICALS, INC. (US) 1989-04-06 WO claimed
EP-0298192-A1 Stable, injectable solutions of vincristine salts Teva Pharmaceutical Industries Limited (IL) 1989-01-11 EP claimed
US-4711782-A Prolonged release microcapsules and their production TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 1987-12-08 US claimed
US-4619935-A Stable oncolytic formulations ELI LILLY AND COMPANY (US) 1986-10-28 US claimed
EP-0010964-A1 Ravidomycin, process of preparation and pharmaceutical compositions containing same AYERST, MCKENNA AND HARRISON INC. (CA) 1980-05-14 EP claimed